Live biotherapeutic/Microbiome Based Therapeutics Market
完整報告名稱與涵蓋範圍
Live biotherapeutic/Microbiome Based Therapeutics Market Size, Share & Trends Analysis Report By Product (VOWST (SER-109), REBYOTA, Visbiome, Other Pipeline Products), By Route of Administration (Oral Therapeutics, Rectal Therapeutics), By Target Disease Indication (Recurrent C. Difficile Infection, Dietary Management of Microbial Imbalance, Other Indications), By Distribution Channel, By End User, By Region, And Segment Forecasts, 2025-2034
報告摘要
The Live biotherapeutic/Microbiome Based Therapeutics Market on a global scale was estimated at USD 73.25 Bn in 2024 and is set to attain USD 142.81 Bn by 2034, with a projected CAGR of 7.04% between 2025 and 2034.
At its core, Live biotherapeutic/Microbiome Based Therapeutics pertains to landscape are mountingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened appetite for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold marked shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Live biotherapeutic/Microbiome Based Therapeutics Market Snapshot
Chapter 4. Global Live biotherapeutic/Microbiome Based Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Live biotherapeutic/Microbiome Based Therapeutics Market Industry Trends
4.10. Global Live biotherapeutic/Microbiome Based Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. VOWST (SER-109)
5.2.2. REBYOTA
5.2.3. Visbiome
5.2.4. Other Pipeline Products
Chapter 6. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 2: By Route of Administration, Estimates & Trend Analysis
6.1. Market Share by Route of Administration, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
6.2.1. Oral Therapeutics
6.2.2. Rectal Therapeutics
Chapter 7. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 3: Target Disease Indication, Estimates & Trend Analysis
7.1. Market Share by Target Disease Indication, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Target Disease Indication:
7.2.1. Recurrent C. Difficile Infection
7.2.2. Dietary management of microbial imbalance
7.2.3. Other Indications
Chapter 8. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
8.2.1. Direct Sales
8.2.2. Pharmacies
8.2.3. Online Platforms
Chapter 9. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 5: By End User, Estimates & Trend Analysis
9.1. Market Share by End User, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:
9.2.1. Healthcare Facilities
9.2.2. Home Healthcare
Chapter 10. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Live biotherapeutic/Microbiome Based Therapeutics Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.2.3. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.2.4. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.2.5. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.2.6. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.3. Europe
10.3.1. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.3.3. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.3.4. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.3.5. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.3.6. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.4.3. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.4.4. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.4.5. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.4.6. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.5. Latin America
10.5.1. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.5.3. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.5.4. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.5.5. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.5.6. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.6.3. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.6.4. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.6.5. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.6.6. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Seres Therapeutics, Inc.
11.2.1.1. Business Overview
11.2.1.2. Key Solution/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. 4D Pharma
11.2.3. Adiso Therapeutics
11.2.4. Alveolus Bio Inc
11.2.5. AOBiome Therapeutics, Inc.
11.2.6. Assembly Biosciences
11.2.7. Azitra
11.2.8. Biomica
11.2.9. Destiny Pharma
11.2.10. Destiny Pharma plc
11.2.11. EnteroBiotix Limited
11.2.12. Finch Therapeutics
11.2.13. Infant Bacterial Therapeutics AB
11.2.14. MaaT Pharma
11.2.15. Microbiotica
11.2.16. OSEL INC.
11.2.17. OxThera
11.2.18. Scioto Biosciences, Inc.
11.2.19. Second Genome
11.2.20. Seres Therapeutics
11.2.21. Servatus Limited
11.2.22. Siolta Therapeutics
11.2.23. Vedanta Biosciences
11.2.24. YSOPIA Bioscience
11.2.25. Other prominent player
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們